Hyderabad: In a petition filed in the US district court, pharma major Astra-Zeneca alleged that city-based Aurobindo Pharma is planning to launch a generic version of its patented drug Daliresp (Roflumilast Tablet 500 mcg).
AstraZeneca, in the petition, alleged that the proposed generic of Daliresp, which is a prescribed medication for adults with severe Chronic Obstructive Pulmonary Disease (COPD) to decrease the number of flare-ups, would infringe the patents on three counts and requested the court to pass an injunction order against manufacturing, importing and selling it in the USA.
AstraZeneca prayed for a permanent injunction, restraining and enjoining Aurobindo Pharma from making, using, selling, offering to sell, or importing any product that infringes the 206, 064, and 142 patent, including Dalisrep. A pharma firm’s senior official said such cases are not uncommon for generic makers in the US.
